Strategy (MSTR) prices €620M euro preferred to buy more Bitcoin as stock nears 7‑month low; options traders eye bear call spreads

7 November 2025

New financing today: Strategy (formerly MicroStrategy) priced 7.75M shares of a 10% euro‑denominated perpetual preferred (“STRE” stock) at €80 per share, raising ~€620M gross / ~€608.8M net to fund more Bitcoin and for working capital. Dividends are cash, quarterly, with compounding if deferred (capped at 18%). Settlement is slated for Nov. 13. ^[1]
Market snapshot: Mid‑day Friday, MSTR traded near $230 (-3.2%) while Bitcoin hovered ~$101K. Earlier in the week, MSTR closed at $246.99, a seven‑month low after a 6.7% one‑day drop. ^[2]
Risk view: Despite the slide, experts told Yahoo Finance that Strategy is not at risk of a forced liquidation of its Bitcoin at current levels. ^[3]
Options angle: Investor’s Business Daily flagged bear call spreads on MSTR as one income‑oriented way to express a cautious view while capping risk. ^[4]

What’s new today: a euro preferred to extend the Bitcoin war chest

Strategy Inc. (Nasdaq: MSTR) this morning priced a euro‑denominated perpetual preferred share offering—10.00% Series A Perpetual Stream Preferred Stock—at €80 per share for 7.75 million shares. Management expects ~€620 million in gross proceeds (~$715 million at €/$ 1.1534) and ~€608.8 million net, with proceeds earmarked for additional Bitcoin purchases and general corporate purposes. The company lists Barclays, Morgan Stanley, Moelis, SG Americas, TD Securities, Canaccord and StoneX as underwriters. ^[5]

A free‑writing prospectus released today details the instrument: stated amount €100 per share; 10% annual dividend paid quarterly in cash when declared; and compounded dividends that ratchet +100 bps per quarter on any unpaid amount (up to 18%) until caught up. Initial settlement is T+5 on Nov. 13. ^[6]

The filing and press release—the latest in a series of 2025 capital raises—underline Strategy’s continued approach: tap capital markets, buy more BTC, rinse and repeat. ^[7]

Stock and Bitcoin move together—again

At publication time, MSTR changed hands around $229.62 (‑3.2% intraday) as Bitcoin (BTC) traded near $100,947. Earlier this week, shares closed at $246.99, the lowest since April 8, after a 6.7% drop on Tuesday as BTC briefly slipped below $100,000. ^[8]

The MSTR‑to‑BTC correlation remains the core story: when Bitcoin wobbles, Strategy’s equity typically magnifies the move because of its leveraged, BTC‑first playbook. ^[9]

Why the shares have been under pressure

MarketWatch highlighted a confluence of headwinds behind this week’s weakness: a sharper‑than‑BTC drawdown in MSTR, investor concern about continued dilution from ongoing equity and preferred issuance, and a narrowing premium of MSTR’s market value relative to the company’s BTC holdings. Tuesday’s tumble to $246.99 crystallized those concerns. ^[10]

Today’s euro preferred pricing may extend those debates. On the one hand, it diversifies funding and bolsters purchasing power if BTC rebounds. On the other, it adds a new fixed dividend obligation—albeit one the company says is payable solely in cash and can compound if delayed—raising questions about coverage should crypto weakness persist. ^[11]

The options angle: income with defined risk

For traders seeking income with capped downside, Investor’s Business Daily has spotlighted bear call spreads in MSTR—selling a call and buying a higher‑strike call with the same expiration—to benefit if shares stall or drift lower. The approach limits risk to the width of the spread minus premium received, and it can be structured above current prices to leave a buffer if MSTR chops sideways. (Options aren’t suitable for all investors.) ^[12]

“Won’t face Bitcoin liquidation,” says expert

While the optics of a falling stock and fresh capital raise are easy headlines, Yahoo Finance reported that an outside expert doesn’t see Strategy facing forced liquidation of its Bitcoin at current market levels. That perspective helps explain why the company leans on perpetual preferreds and equity—financing that doesn’t require pledging BTC as collateral in the way some margin structures would. ^[13]

Context: MicroStrategy is now “Strategy”

If the name looks new, it is. The company rebranded from “MicroStrategy Incorporated” to “Strategy Inc.” earlier this year and completed a legal name change in August, while MSTR remains the Class A common stock ticker on Nasdaq. ^[14]

What to watch next

Settlement (Nov. 13): Confirmation that the STRE deal closes on schedule. ^[15]
Dividend mechanics: The quarterly cash dividends begin Dec. 31, 2025 for STRE. Any deferral triggers compounding (up to 18%) until made whole. ^[16]
BTC price path: With BTC near $100K, larger swings could amplify MSTR’s moves in either direction.
Further issuance: 2025 has already seen multiple preferred series and shelf updates; investors will parse any new filings for size, ranking and potential dilution. ^[17]

By the numbers (as of publication)

MSTR: $229.62 intraday; day range $220.12–$238.42.
BTC‑USD: $100,947; day range $99,303–$102,808.
STRE terms:€80 issue price; €100 stated amount; 10% coupon; quarterly cash dividends with compounding if deferred; settlement Nov. 13. ^[18]

This article is for information only and is not investment advice.

EASY Crypto Options Trading Strategy Tutorial (Very SIMPLE Guide)

Watch this video on YouTube.

References

1. www.businesswire.com, 2. www.morningstar.com, 3. finance.yahoo.com, 4. www.investors.com, 5. www.businesswire.com, 6. assets.contentstack.io, 7. www.strategy.com, 8. www.morningstar.com, 9. www.morningstar.com, 10. www.morningstar.com, 11. www.businesswire.com, 12. www.investors.com, 13. finance.yahoo.com, 14. www.strategy.com, 15. www.businesswire.com, 16. www.businesswire.com, 17. www.strategy.com, 18. assets.contentstack.io

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

INTC: Intel Eyes AI Chip Partnership With Tesla as Shares Rise on Premarket Buzz
November 8, 2025, 1:00 AM EST. Intel shares rose more than 2% in premarket trading after reports of a potential AI chip partnership with Tesla to expand manufacturing capacity. While no formal agreement has been announced, early discussions have buoyed investor sentiment as automakers seek AI hardware capacity. A deal could help Intel boost its foundry services and compete with Nvidia and AMD in the fast-growing AI-chip market, fitting its broader turnaround plan to widen manufacturing leadership through external partnerships. GuruFocus notes one-year targets from 36 analysts averaging $35.04 (high $50, low $18), implying a downside of about 6% from the current price of $37.24. GuruFocus' GF Value estimates Intel at $23.64 in one year, signaling a larger downside (~36%).
UnitedHealth Group (UNH) Valuation Check After Recent Price Weakness: Undervalued or Risks Ahead?
November 8, 2025, 12:58 AM EST. UnitedHealth Group (UNH) has fallen roughly 12% over the last month, with volatility and a weak year-to-date showing longer-term underperformance vs the market. This raises questions about growth prospects and whether the pullback marks a long-run undervaluation or a change in sentiment. Shares sit below recent highs and some analyst targets, fueling debate about intrinsic value. On the bull side, consensus fair value literature points to meaningful upside (e.g., well above current close) supported by strong free cash flow and regulatory visibility that could sustain expansion. On the flip side, risks like Medicare Advantage margin pressure and potential missteps with new risk models could derail the recovery. Investors may weigh a potential buying opportunity against these headwinds before changing their watchlists.
Spot Solana ETFs Draw Strong Inflows as SOL Slips; BSOL Tops Week
November 8, 2025, 12:38 AM EST. US spot Solana ETFs drew solid demand in their first week, even as SOL slid about 20% from a $205 high to around $165. The price weakness came as BTC and ETH fell roughly 6% and 12%. CoinShares data show weekly inflows of about $421 million, making BSOL the top crypto ETF of the week. Bitwise's BSOL attracted roughly $199 million in fresh funds, starting with nearly $223 million seed; GSOL pulled in $2.2 million and carries $102 million AUM after converting from a closed-end product. Fees run 0.20% for BSOL and 0.35% for GSOL (vs 1.5% on GBTC/ETHE). K33's Vetle Lunde called the launch a "very solid" start amid broader crypto fund outflows.
Kennedy-Wilson (KW) Valuation Revisited After 24% Rally: Is the Stock Undervalued?
November 8, 2025, 12:36 AM EST. Kennedy-Wilson Holdings (KW) surged over 24% this week, renewing investor focus on its real estate management story. Despite a negative one-year TSR, near-term momentum suggests renewed optimism, while longer-term performance remains a question mark. The stock trades near analyst targets, with revenue gains yet ongoing net income challenges. Our narrative-based fair value is $11.00, implying the shares may be undervalued versus the story, but a DCF view puts fair value at about $1.31, signaling potential valuation gaps. The current price at $9.40 sits above the DCF value but below the narrative target, underscoring contrasts between capital deployment strength, recurring fees, and margin expansion against macro risks like rental demand shifts and tighter credit. Consider the risk-reward carefully.
Merus (MRUS) Valuation Under Scrutiny After Recent Share Rally
November 8, 2025, 12:34 AM EST. Merus (MRUS) has surged, with a 90-day return of 48.8%, and a year-to-date gain of 125.1%, fueling optimism about growth prospects. The stock's momentum is backed by a 74.7% 1-year TSR and a 624.7% five-year TSR, but valuation remains contentious. Merus trades at a price-to-book (P/B) of 9.3x, well above the US biotech industry average of 2.4x, though it sits closer to peers at 13.3x. The raised multiple implies aggressive growth expectations or breakthrough potential, yet the company remains unprofitable. If fundamentals temper expectations or clinical data disappoints, multiple re-rating could hit the stock. With shares near analyst targets, risk-reward hinges on future profitability and trial outcomes rather than past momentum.